2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.
Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses current CAR T-cell therapies in multiple myeloma.
Two CAR T-cell therapies are currently FDA approved, including idecabtagene vicleucel (ide-cel; Abecma), which was approved in March 2021 for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, Raje explains. In February 2022, ciltacabtagene autoleucel (cilta-cel; Carvykti) received approval for the treatment of adult patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy, Raje adds.
The indications for cilta-cel and ide-cel are for patients who have been exposed to a majority of treatment options, including lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), and an anti-CD38 monoclonal antibody, Raje concludes.